Morphic Holding Inc

Morphic — Technical Presentation (October 2023)

32 slides from Morphic's technical presentation, Oct 12, 2023

  1. Slide 1: EMERALD-1 Full Data Presentation

    EMERALD-1 Full Data Presentation October 12, 2023

  2. Slide 2: Forward-Looking Statements

    This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements regarding the timing and success of Morphic’s ongoing clinical trials and related data, updates

  3. Slide 3: Phase 2a Study Designed to Confirm Efficacy Signal: Results Exceeded Expectations

    • Primary endpoint achieved, with consistent and expected clinical improvement seen across key measures • PK in patients consistent with healthy volunteers • RO and T-cell subsets consistent with healthy volunteers • Generally well tolerated with no safety signal observed • Further clinical improvem

  4. Slide 4: Agenda

    • Welcome and Introduction – Chris Erdman, SVP Investor & Corporate Communications • Trial Design, Patient Disposition, Safety, PK/PD – Dr. Brihad Abhyankar, SVP Clinical Development, Morphic Therapeutic • Detailed Clinical Efficacy Results – Dr. Bruce Rogers, President, Morphic Therapeutic • Conclu

  5. Slide 5: EMERALD-1 Trial Design and Patient Disposition

    EMERALD-1 Trial Design and Patient Disposition

  6. Slide 6: MORF-057 Phase 2a EMERALD-1 Study Design

    6 MORF-057 Phase 2a EMERALD-1 Induction Period (12 weeks) Maintenance Period (40 weeks) Primary Endpoint: Change in RHI measured at 12 weeks Secondary Endpoint: Change in the mMCS from baseline at w12 Open-label Extension Study (6 months) Safety Follow-Up Period Screening Period Target enrollment: 3

  7. Slide 7: Baseline Patient Demographics: Moderately-to-Severely Active UC Population

    Category Patients, N=35 Age, mean ± SD Years 39.2 ± 14.1 Sex, n (%) Female 16 (45.7) Geography, n (%) Poland United States 28 (80.0) 7 (20.0) Duration of disease, mean ± SD Years 7.5 ± 8.0 Extent of disease, n (%) Proctosigmoiditis L-sided colitis Pancolitis 12 (34.3) 10 (28.6) 10 (28.6) RHI Score,

  8. Slide 8: Demographics and Baseline Characteristics by Prior Treatment Status & MES

    8 Demographics and Baseline Characteristics by Prior Treatment Status & Mayo Endoscopic Score Baseline Characteristics Main Cohort (N=35) AT-N (N=21, 60%) AT-E (N=14, 40%) MES =2 (N=18, 51.4%) MES =3 (N= 17, 48.6%) Age, years, mean (SD) 39.2 (14.10) 39.9 (14.89) 38.3 (13.32) 40.1 (11.22) 38.4 (16.95

  9. Slide 9: Safety and Tolerability

    ZAMORPHIC Safety and Tolerability

  10. Slide 10: MORF-057: Generally Well-Tolerated in EMERALD-1, No Safety Signal Observed

    Endpoint Patients, N = 35 Patients with ≥1 TEAE, n (%) 12 (34.3) Serious TEAEs, n (%) 0 Patients with AE leading to death, n (%) 0 Patients with any grade 3 TEAEs, n (%) UC exacerbationa 2 (5.7) Common TEAEs (>5%), n (%) UC exacerbation Anemiab,c 4 (11.4) 3 (8.6) Treatment-related TEAE, n (%) 2 (5.7

  11. Slide 11: PK/PD and Biomarker Data

    PK/PD and Biomarker Data

  12. Slide 12: Patient α4β7 Receptor Occupancy Consistent with Healthy Volunteer RO

    • a4β7 RO achieved early and sustained saturating levels • a4β1 RO remained at low levels • No lymphocytosis or changes to circulating naïve T-cells were observed • a4β1 projected RO was below the limit of quantitation with mean trough value estimated to be <15% 12 Patient a4β7 Receptor Occupancy (R

  13. Slide 13: Substantial Lymphocyte Subset Changes Consistent With Engagement Of α4β7

    13 Substantial Lymphocyte Subset Changes Observed, Consistent With Engagement Of α4β7 0 25 50 75 100 125 150 Weeks N or m al iz ed % 0 2 6 12 0 25 50 75 100 125 150 200 300 400 Weeks N or m al iz ed % P = 0.0039 ** 0 2 6 12 P = 0.0298 * 0 25 50 75 100 125 150 200 300 400 Weeks N or m al iz ed % 0 2

  14. Slide 14: Fecal Calprotectin Decreases Correlated with Disease Improvement

    14 Fecal Calprotectin Decreases Correlated with Disease Improvement 19% 54% 75% Overall (n=29): 35% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Non- Responder (n=16) Clinical Response (n=13) Clinical Remission (n=8) -11% -86% -89% Overall (n=27): -56% -100% -90% -80% -70% -60% -50% -40% -30% -20% -1

  15. Slide 15: Expected Changes in C-Reactive Protein Observed

    15 Expected Changes in C-Reactive Protein Observed 18% 33% 33% Overall (n=17): 24% 0% 5% 10% 15% 20% 25% 30% 35% 40% Non-Responder (n=11) Clinical Response (n=6) Clinical Remission (n=3) No inclusion/exclusion criteria for CRP levels: n= 17 pts with baseline > 3 mg/L Patients experiencing clinical r

  16. Slide 16: Clinical Efficacy Results

    ZAMORPHIC Clinical Efficacy Results

  17. Slide 17: Robarts Histopathology Index for UC

    • RHI: a validated histology index derived from the Geboes Score and designed to be reproducible and responsive to clinically meaningful change in disease activity in UC over time • Calculated by evaluating 4 centrally read, individually weighted histologic items, each on a scale from 0 to 3 • RHI =

  18. Slide 18: Modified Mayo Clinic Score for UC

    18 Modified Mayo Clinic Score for UC • Modified Mayo Clinic Score (mMCS) – Three component score – 0 to 9 scale with moderate to severe UC 5 to 9 – Clinical Remission • SFS ≤ 1 • RBS = 0 • MES ≤ 1 without friability – Endoscopic Response / Improvement: MES ≤ 1 – Symptomatic Remission: SFS = 0 (or =

  19. Slide 19: Primary Endpoint Met with High Statistical Significance

    19 Endpoint @ Week 12 Overall (N=35) Change in RHI, Mean (SD) -6.4 (11.18) p=0.0019 RHI remission, n (%) 8 (22.9%) Clinical response (mMCS)1, n (%) 16 (45.7%) Clinical remission (mMCS)2, n (%) 9 (25.7%) Endoscopic Response/Improvement3, n (%) 9 (25.7%) Change from baseline to Week 12 in the Modified

  20. Slide 20: EMERALD-1 Efficacy Results by AT Status and MES

    20 EMERALD-1 Efficacy Results by AT Status and MES Endpoint @ Week 12 Overall N=35 AT-naïve n=21 AT- experienced n=14 MES =2 n=18 MES =3 n= 17 Change in RHI, mean ± SD -6.4 ± 11.2 -7.4 ± 11.9 -4.8 ± 10.3 -6.9 ± 12.1 -5.8 ± 10.4 RHI change ≥ 7 points, n (%) 17 (48.6) 12 (57.1) 5 (35.7) 10 (55.6) 7 (4

  21. Slide 21: Consistent Across-the-Board Efficacy Signals Observed

    21 Consistent “Across-the-Board” Efficacy Signals Observed Subgroup AT-Experienced Yes (n=14) No (n=21) Corticosteroid Use at Baseline Yes (n=9) No (n=26) Baseline MES 3 (n=17) 2 (n=18) Mean Change (95% CI) -4.8 (-10.7, 1.1) -7.4 (-12.8, -2.0) -5.2 (-11.1, 0.7) -6.8 (-11.7, -1.8) -5.8 (-11.1, -0.4)

  22. Slide 22: Clinical Improvement in >75% of All Patients

    22 Clinical Improvement in >75% of All Patients, Regardless of Prior Therapy and Baseline MES 77% 46% 26% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Improvement in mMCS Clinical Response Clinical Remission Overall Clinical Improvement AT-Naïve: n=21; AT-Experienced: n=14 76% 52% 43% 79% 36% 0% 0% 10% 20

  23. Slide 23: Change in Central mMCS By Patient from Baseline

    23 Change in Central mMCS By Patient from Baseline at Week 12 -7 -6 -5 -4 -3 -2 -1 0 1 2 Ch an ge in m M CS fr om B as el in e at W ee k 12

  24. Slide 24: Change in Central mMCS from Baseline by Subgroup at Week 12

    24 Change in Central mMCS from Baseline by Subgroup at Week 12 -7 -6 -5 -4 -3 -2 -1 0 1 2 Ch an ge in m M CS fr om B as el in e at W ee k 12 AT-Naïve Baseline MES = 3 AT-Naïve Baseline MES = 2 AT-Experienced Baseline MES = 3 AT-Experienced Baseline MES = 2 Response   Remission 

  25. Slide 25: Data Beyond 12 Weeks

    ZAMORPHIC Data Beyond 12 weeks

  26. Slide 26: Symptomatic Remission By AT-Status

    26 Symptomatic Remission By AT-Status: Week 44 Intent to Treat (ITT): Denominator includes all enrolled patients (N=35) As observed: Denominator includes only patients who completed the visit 14.3 7.1 11.4 42.9 7.1 28.6 47.6 7.1 31.4 42.9 21.4 34.3 47.6 28.6 40 42.9 28.6 37.1 42.9 21.4 34.3 3/21 9/2

  27. Slide 27: Symptomatic Remission By Baseline MES

    27 Symptomatic Remission By Baseline MES: Week 44 ITT: Denominator includes all enrolled patients (N=35) As observed: Denominator includes only patients who completed the visit 11.111.8 11.4 44.4 11.8 28.6 38.9 23.5 31.4 44.4 23.5 34.3 55.6 23.5 40 55.6 17.6 37.1 50 17.6 34.3 2/18 8/18 7/18 8/18 10/

  28. Slide 28: PRO2 Scores by Subgroup

    28 PRO2 (SFS+RBS) Scores by Subgroup: Week 44 PRO2 (Sum of Stool Frequency and Rectal Bleeding Scores) by AT-Status PRO2 (Sum of Stool Frequency and Rectal Bleeding Scores) by Baseline Endoscopy Score 4.2 3 1.8 1.8 1 0.9 1.1 0.9 4.2 4.2 3.3 3.1 3.1 2.4 2.6 2.2 2.1 1.5 2 1.3 2.3 1.5 2.3 1.4 18 18 18

  29. Slide 29: Phase 2a Study Designed to Confirm Efficacy Signal: Results Exceeded Expectations

    • Primary endpoint achieved, with consistent and expected clinical improvement seen across key measures • PK in patients consistent with healthy volunteers • RO and T-cell subsets consistent with healthy volunteers • Generally well tolerated with no safety signal observed • Further clinical improvem

  30. Slide 30: Corporate Update

    Corporate Update

  31. Slide 31: MORF-057 and Corporate Guidance

    31 MORF-057 and Corporate Guidance MORF-057 • EMERALD-1 maintenance phase continuing on track • EMERALD-2 enrolling on track • 1H25 primary endpoint data • Phase 2b in Crohn’s on track for ’24 initiation EMERALD-1 Phase 2a EMERALD-2 Phase 2b Crohn’s Phase 2b MORF-057 Phase 3 MORF-057 Phase 3 MORF-05

  32. Slide 32: Q&A Participants

    32 Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics. His research focus is the design, conduct and execution of large-scale randomized controlled trials (RCTs) in Crohn’s disease (CD) and ulcerative colitis (UC), and over the past 30 years, has been

Morphic Holding — Technical Presentation (October 2023) on 6ix